Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas

Cancer

Volumn 110, Issue 12, 2007, Pages 2793-2798

  Shoji, Fumihiro ^a   Yoshino, Ichiro ^a   Yano, Tokujiro ^b   Kometani, Takuro ^a   Ohba, Taro ^a   Kouso, Hidenori ^a   Takenaka, Tomoyoshi ^a   Miura, Naoko ^a   Okazaki, Hiroshi ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Saga Prefectural Hospital Koseikan   (Japan)

Author keywords

Epidermal growth factor receptor gene mutation; Gefitinib; Lung adenocarcinomas; Serum carcinoembryonic antigen concentration

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 37048998597     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23101     Document Type: Article

References (33)

1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
7. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-2501.
8. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
9. Okamoto T, Nakamura T, Ikeda J, et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer. 2005;41:1286-1290.
10. International Union Against Cancer. TNM classification of malignant tumors. 5th edition. New York: John Wiley & Sons; 1997.
11. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93:355-363.
12. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9-S15.
13. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
14. Suzuki S, Dobashi Y, Sakurai H, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103:1265-1273.
15. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439-462.
16. Concannon JP, Dalbow MH, Hodgson SE, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer. 1978;42:1477-1483.
17. Hammarstrom S, Baranov V. Is there a role for CEA in innate immunity in the colon? Trends Microbiol. 2001;9:119-125.
18. Abbasi AM, Chester KA, MacPherson AJ, et al. Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J Pathol. 1992;168:405-411.
19. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327-334.
20. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) an other prognostic indicators in squamous cell lung cancer. Lung Cancer. 1993;10:21-33.
21. De Angelis G, Bigioni D, Leonatti C, et al. Serum carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and neuron specific enolase (NSE) for monitoring lung cancer and correlation with metastasis. J Tumor Marker Oncol. 1988;3:5-10.
22. Molita R, Agusti C, Mane JM, et al. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers. 1994;9:96-101.
23. Yoshino I, Ichinose Y, Nagashima A, et al. Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation. J Thorac Oncol. 2006;1:825-831.
24. Singh RK, Tsan R, Radinsky R. Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis. Clin Exp Metastasis. 1997;15:140-150.
25. Abdel-Aziz MM, Lotfy ML, EI-Kady IM, et al. Mutant p53 protein in the serum of patients with colorectal cancer: correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev. 2006 Apr 20; [Epub ahead of print].
26. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081-8092.
27. Okabe T, Okamoto I, Tamura K, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007;67:2046-2053.
28. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327-334.
29. Wirth T, Soeth E, Czubayko F, et al. Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis. 2002;19:155-160.
30. Ordonez C, Screaton RA, Ilantzis C, et al. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 2000;60:3419-3424.
31. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
32. Cappuzzo F, Margrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:1133-1141.
33. Jiang J, Greulich H, Janne PA, et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005;65:8968-8974.